DUARTE, Calif.--(BUSINESS WIRE)--Researchers at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, have developed a tool that could predict if older adults with early-stage breast cancer will develop a severe or deadly reaction to chemotherapy.

This first-of-its-kind risk assessment tool called the Cancer and Aging Research Group-Breast Cancer (CARG-BC) Score helps oncologists make personalized treatment recommendations. Oncologists can discuss the score and its significance with early-stage breast cancer patients age 65 or older. Together, an informed decision about chemotherapy can be made as treatment benefit is weighed against quality of life concerns, said Mina Sedrak, M.D., M.S., co-first author of the new study and deputy director of clinical trials for the Center for Cancer and Aging Research at City of Hope.

Despite remarkable advances in cancer treatment, tools to characterize the toxicity of cancer therapies have remained virtually unchanged for the past 20 years, Sedrak said. This is a new precision medicine tool. Rather than basing treatment decisions and care on demographic data for a disease, we now can offer each elderly, early-stage breast cancer patient individualized toxicity information that could help align treatment with their goals for lifestyle, quality of life, longevity and other priorities.

More than 72% of older patients with cancer reported that they would not choose cancer treatment that results in functional impairment even if it improves survival, Sedrak said.

If the risk of chemotherapy toxicity is known in advance, oncologists and patients could work together to decide whether chemotherapy is the right choice. Treatment modifications such as dose reductions and longer periods between chemotherapy delivery could be recommended. Older patients could also preemptively be referred for supportive care interventions such as consults with physical therapists, occupational therapists, social workers and pharmacists, who could evaluate potential drug interactions with existing medications for chronic ailments. Additionally, patients could have someone evaluate their home for safety or necessary modifications.

The study, published on Jan. 14 in the Journal of Clinical Oncology, spanned 16 institutions across the nation, with City of Hope being the lead institution. It included 473 patients age 65 or older with Stage 1-3 breast cancer (283 in development cohort; 190 in validation cohort). They were all treated with chemotherapy either before or after surgery and were evaluated for geriatric and clinical symptoms predictive of severe (grade 3), debilitating (grade 4) or deadly (grade 5) side effects due to chemotherapy.

Though chemotherapy is an effective way to treat early-stage breast cancer, it also carries a risk of side effects. There is a delicate balance between the benefits of chemotherapy and the harm of possible side effects, said Canlan Sun, M.D., Ph.D., senior author of the study and associate research professor in the Department of Supportive Care Medicine at City of Hope.

The development of severe chemotherapy toxicity not only can harm the patient, but it can also compromise an older adults ability to complete the full course of chemotherapy, possibly reducing the potential benefit of the cancer treatment, she added.

Sedrak noted that most women with early stage breast cancer have a potentially curable disease and some would benefit from chemotherapy after surgery. Unfortunately, older adults aged 65 and over, who comprise about half of all breast cancer diagnoses, are significantly less likely to be offered chemotherapy compared to younger patients sometimes because their doctors fear they wont be able to tolerate it, he said. Older adults are also underrepresented in cancer trials, and we know little about how best to treat this heterogenous group.

The CARG-BC score is derived by combining eight disease and patient-reported predictors: use of an anthracycline chemotherapy, Stage 2 or 3 breast cancer, longer planned treatment duration, abnormal liver function, low hemoglobin, falls, limited walking ability and lack of social support.

This risk prediction model is an extension of prior work from the national Cancer and Aging Research Group led by scientists at City of Hope and elsewhere. As a National Cancer Institute-designated comprehensive cancer center, City of Hope offers integrated, multidisciplinary care that includes supportive care services addressing physical and emotional issues that can arise during and after treatment.

The newly developed CARG-BC score outperformed existing measures of patient performance status that are widely used in oncology such as the Karnofsky performance status or Eastern Cooperative Oncology Group performance status, both of which were developed and validated in younger patients.

Those clinician-based eyeball tests are imprecise and subjective, Sedrak said. They do not detect important factors such as functional reserve or the ability to respond to stress, which vary greatly between older patients of the same chronological age and are valued by patients and caregivers.

As a next step, the researchers will look to improve the chemotherapy toxicity risk assessment tool with more biological markers. They will attempt to identify biomarkers that could predict severe or deadly side effects to chemotherapy. They are working to identify interventions to support elderly breast cancer patients so that they derive the most benefit and the least toxicity from chemotherapy.

The researchers will also continue their efforts to improve access to cancer clinical trials for all patients, leveraging new innovations in technology and widely used social media networks.

The title of the study is Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer (https://doi.org/10.1200/JCO.20.02063). It was supported by the National Institute on Aging (NIA R01 AG037037, K76 AG064394, K23AG038361, K24 AG055693, K24 AG056589), National Cancer Institute (K12CA001727, K12CA167540), National Institutes of Health (R21 AG059206), Breast Cancer Research Foundation, Susan G. Komen for the Cure (CCR14298143), American Cancer Society (125912-MRSG-14-240-01-CPPB) and Center for Cancer and Aging Research at City of Hope.

This research would not have been possible without the foundational scientific contributions made by the late Arti Hurria, M.D., former director of City of Hopes Center for Cancer and Aging Research.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies, and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hopes exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

See original here:
City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults...